France has not launched a new early-access scheme. It has changed the operating rules of an established route that can place innovative medicines into funded clinical use before conventional reimbursement is complete. For biotech companies, the consequence is simple: reimbursement evidence strategy now needs to begin earlier.
| The reimbursement point: Early access is not a substitute for reimbursement. It is a period in which reimbursement-relevant evidence can be created, tested and refined while patients are already receiving treatment. The companies that treat it as an administrative bridge risk wasting one of the most valuable evidence windows in the French market. |
France changed the rules on 1 September 2026
On 1 September 2026, Decree No. 2026-448 of 3 June 2026 came into force. The decree harmonises and simplifies parts of France’s early-access and compassionate-access framework, including the way applications are routed between the Haute Autorité de Santé (HAS) and the Agence nationale de sécurité du médicament et des produits de santé (ANSM).
The change matters because accès précoce already sits in a commercially unusual place: after enough clinical evidence exists to support a strong presumption of benefit, but before ordinary French reimbursement has necessarily been completed. The 2026 HAS/ANSM industry guide explicitly describes early access as an exceptional route that can provide automatic coverage by national solidarity when the legal conditions are met.
For a biotech CEO, CMO or market-access lead, the mistake would be to read this as a procedural update. The more important question is what France is asking the company to know — and to measure — before routine reimbursement begins.
Who can use the French early-access route?
The route applies to medicinal products, not medical devices or digital technologies. According to HAS, the medicine must address a serious, rare or disabling disease; there must be no appropriate treatment; treatment cannot be deferred; and the medicine must be presumed innovative, including in relation to a clinically relevant comparator. For pre-authorisation applications, efficacy and safety must also be strongly presumed from therapeutic trial results.
Pre-AMM early access: the indication does not yet have marketing authorisation. The company must have filed, or commit to file, an MA application within the permitted period; the statutory maximum is two years from the grant of early access.
Post-AMM early access: the indication has marketing authorisation but is not yet reimbursed under ordinary arrangements. The company must have filed, or commit to file within one month of the MA, for inclusion on the relevant reimbursement list.
The authorisation itself is generally granted for a maximum of one year and may be renewed; renewal applications must be submitted no later than three months before expiry.
| Why this is a biotech issueFor a small or mid-sized biotech, France can become a live market-access market while the European regulatory and reimbursement story is still developing. That creates an opportunity — but also a sequencing risk. Comparator choice, endpoint interpretation, patient selection and evidence collection can no longer be postponed until after the EMA decision. |
The pathway at a glance
| Stage | What happens | Indicative clock | Reimbursement consequence |
| 1. Pre-deposit | Optional joint HAS/ANSM meeting for first pre-AMM applications; eligibility, dossier, timing and PUT-RD can be discussed. | Usually 2–3 months before filing | First chance to align clinical evidence with the later reimbursement question. |
| 2. Submission | Electronic filing through the SÉSAME single gateway. New 2026 dossier structures distinguish initial, renewal and new-data submissions. | Immediate once dossier is ready | Administrative quality affects the start of the statutory clock. |
| 3. Admissibility | HAS checks whether the application is administratively complete. | 10 working days | An incomplete file delays the entire market-access sequence. |
| 4. Assessment | HAS assesses the access criteria; for relevant pre-AMM cases ANSM provides the efficacy/safety opinion. The Transparency Commission advises before the HAS decision. | 90 days from complete dossier; may be extended in exceptional volume | The comparator and definition of innovation are already being tested before routine reimbursement. |
| 5. Decision & launch | If granted, the authorisation includes the indication and PUT-RD. The company must make the medicine available. | Medicine available within max. 2 months after AAP | Patients enter funded use before ordinary reimbursement is finished. |
| 6. Evidence generation | Prescribers, pharmacists and patients contribute data under the PUT-RD; periodic synthesis reports are submitted. | Throughout early access | A real-world evidence window opens while reimbursement is still evolving. |
| 7. Transition | Pre-AMM access can continue through MA; the company proceeds to conventional listing, HTA and price/reimbursement arrangements. | Product-specific | The early-access evidence should feed, not sit apart from, the reimbursement strategy. |
The most important part is not the 90-day clock
HAS states that administrative admissibility is determined within 10 working days and that the assessment period is 90 days from acknowledgment of a complete application. The clock matters. But for reimbursement strategy, the more valuable feature is the ability to engage before filing.
For first pre-AMM applications, HAS and ANSM offer joint pre-deposit meetings. The agencies describe them as free, confidential and optional, but strongly encouraged. The meeting can cover eligibility, dossier content, filing timetable, and the type of data to be collected through the Protocole d’utilisation thérapeutique et de recueil de données (PUT-RD). HAS advises holding the meeting around two to three months before the planned filing.
That is where the reimbursement conversation should begin. Not with price. With the question the payer will eventually need answered.
PUT-RD: the evidence window biotech companies should not waste
The HAS/ANSM guide is unusually clear on one point: data collected under the PUT-RD are not intended to replace a clinical trial. They are collected in routine care.
That distinction is strategically important. A pivotal trial answers the regulatory efficacy and safety question. The early-access dataset can help answer a different set of questions that are often closer to reimbursement: who receives the medicine in practice, how it is sequenced, which patients benefit, how long benefit persists, what adverse events and resource use occur, and what patients report about their quality of life.
Patient characteristics and treatment eligibility in real practice.
Previous and concomitant treatments, sequencing and duration.
Effectiveness and durability outside the pivotal trial population.
Adverse events, discontinuation and treatment-management burden.
Quality of life and other patient-relevant outcomes, where appropriate.
Variables that can later support the clinical and economic interpretation of reimbursement value.
| The Odelle viewThe best PUT-RD is not the longest dataset. It is the smallest credible dataset that closes the payer’s most important remaining uncertainty. For biotech reimbursement, that usually means working backwards from the likely HAS comparator, target population, treatment pathway and economic consequence — then deciding what must be captured prospectively. |
Rare disease biotech has an additional opportunity: BaMaRa
France has also developed a specific treatment dataset within BaMaRa / the Banque Nationale de Données Maladies Rares (BNDMR). The SDM-T is designed to support evaluation of medicines in early access, compassionate access and post-listing follow-up.
For rare-disease biotech, this creates something more valuable than another registry obligation: a potential evidence continuum. The same national infrastructure can help connect early use with later post-reimbursement follow-up. HAS notes that the BaMaRa PUT-RD contains a core set of predefined fields plus selected customisable variables, including medicine-effectiveness variables that should be discussed before submission.
What changed operationally in September 2026?
A single electronic gateway: applications are submitted through SÉSAME rather than being routed separately to each authority.
Three distinct dossier templates now cover the initial application, renewal, and submission of new data; continuity after MA and withdrawal use dedicated SÉSAME forms.
The previous single dossier template is accepted only during the transition period to 1 October 2026.
New synthesis-report templates apply to renewal applications submitted on or after 24 October 2026.
The revised rules simplify HAS/ANSM coordination, including cases where a favourable CHMP opinion is already available.
The underlying evidence obligation remains: innovation, urgency, comparator relevance and real-world follow-up still need to be demonstrated coherently.
Why reimbursement teams should be involved before regulatory approval
The French sequence exposes a common weakness in biotech launch planning. Clinical development is often designed first; regulatory strategy is layered on next; reimbursement is invited in once the pivotal programme is largely fixed.
France makes that sequencing increasingly difficult to defend. A company seeking early access may have to explain the clinically relevant comparator and presumed innovation, agree to a prospective data strategy, and commit to the next reimbursement step while the regulatory programme is still moving.
The better sequence is:
| Pivotal evidence → French payer question → early-access dataset → HAS assessment → price & reimbursement → post-listing evidence |
That does not mean a biotech should optimise a clinical programme for one country. It means the European evidence plan should be sufficiently deliberate that France does not become the first place where anyone asks whether the trial endpoints, comparator, and follow-up can support reimbursement.
A practical reimbursement playbook for biotech SMEs
Start the French reimbursement work before the early-access filing. Map the likely HAS comparator, target population, treatment sequence and evidence gaps while the clinical dossier can still be interpreted or supplemented intelligently.
Use the pre-deposit meeting as an evidence-design meeting, not merely a procedural check. Arrive with a clear view of what the PUT-RD should learn and why those variables matter to later reimbursement.
Design the PUT-RD around uncertainty. Separate what the pivotal trial already proves from what payers still need to understand in routine practice.
For rare disease, assess BaMaRa early. If SDM-T is relevant, engage the BNDMR and the relevant rare-disease network before filing so that custom variables are agreed prospectively.
Plan the transition to ordinary reimbursement from day one. Early access, marketing authorisation, HAS assessment, CEPS pricing and post-listing evidence should be treated as one evidence sequence, not as independent projects.
The strategic conclusion
France’s September 2026 reform is easy to underestimate because much of it looks administrative. For biotech companies, however, the important change is not the form. It is the timing.
A medicine can now move through a more integrated early-access process while the company is simultaneously approaching marketing authorisation, routine reimbursement and pricing. The evidence generated during that interval can become commercially important — but only if the right questions were asked before the first patient entered the programme.
The reimbursement strategy therefore begins earlier than the reimbursement submission. For biotech, that is the real significance of France’s revised framework.
| Odelle TechnologyOdelle works with biotech companies to connect clinical evidence, health economics, HTA and reimbursement strategy before launch decisions become irreversible. In France, that means working backwards from the likely HAS and payer questions to define the comparator, evidence gaps, early-access data strategy and route into routine reimbursement. |
Official sources and practical links
HAS — Accès précoce à un médicament
Current official HAS landing page, updated 1 September 2026.
HAS / ANSM — Accès précoce des médicaments: accompagnement des laboratoires, Guide 2026
Detailed industry guide covering pre-deposit meetings, submission, PUT-RD, decision process and transition after MA.
Légifrance — Décret n° 2026-448 du 3 juin 2026
Official decree that entered into force on 1 September 2026.
HAS SÉSAME — submission portal
Electronic gateway for early-access submissions and pre-deposit requests.
Légifrance — Social Security Code, early coverage under Article L162-16-5-1
Legal basis for derogatory Assurance Maladie coverage of medicines with early-access authorisation.
Official rare-disease treatment dataset used for early access, compassionate access and post-listing follow-up.